Introduction {#s1}
============

Myocardial infarction (MI) is a leading cause of death worldwide, and is a multifactorial disease, influenced by genetic and environmental factors [@pone.0104608-Lopez1]. The main risk factors for MI include hypertension, hypercholesterolemia, diabetes, obesity, and smoking. In addition, recent studies have also shown the importance of genetic factors caused by polymorphisms in the pathogenesis of MI [@pone.0104608-Gu1]--[@pone.0104608-Wang2].

Apolipoprotein E (Apo E) is a serum glycoprotein found in circulating chylomicrons (remnants), very low density lipoproteins, intermediate density lipoproteins and high-density lipoproteins [@pone.0104608-Scott1]. ApoE is considered as an excellent candidate gene for studying the susceptibility to coronary heart disease (CHD) and MI because of its pivotal roles in the metabolisms of cholesterol and triglyceride [@pone.0104608-Stampfer1]. The most extensively studied polymorphism in the ApoE gene codes for three variant alleles: ε2, ε3 and ε4, which yield six possible genotypes: ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, ε3/ε4 and ε4/ε4 in general population [@pone.0104608-Lahiri1]. The products of the three alleles differ in their properties such as their affinity for binding low density lipoprotein receptors and lipoprotein particles; therefore, this ApoE polymorphism could affect the serum levels of cholesterol and triglyceride, thus contributing to the progression of atherosclerosis. In fact, ApoE polymorphisms have been found to be associated with many lipid-related diseases and cardiovascular and cerebrovascular diseases [@pone.0104608-Zhang1]--[@pone.0104608-Zhu1].

Numerous studies have been conducted to explore the association of this ApoE polymorphism and CHD; some of the studies found a significant association between the ApoE ε4 allele and CHD [@pone.0104608-Takeuchi1]--[@pone.0104608-Atabek1]. A meta-analysis conducted in 2004 provided evidence that the ε4 allele of ApoE was a risk factor for the development of CHD [@pone.0104608-Song1]. Another meta- analysis conducted in 2013 further confirmed this finding in a Chinese population [@pone.0104608-Yin1]. However, no meta-analysis has been conducted to explore the association between this ApoE gene polymorphism and MI. In spite of the presence of advanced CHD, only a subset of patients develops MI during their life. The reasons for these individual differences in susceptibility to MI are poorly understood. Therefore, it is important to explore the association between ApoE gene polymorphisms and MI. In fact, a number of case-control studies have been conducted to clarify the association between ApoE gene polymorphisms and MI [@pone.0104608-Utermann1]--[@pone.0104608-Zende1]; however, the results are inconsistent. Therefore, we conducted this meta-analysis including all of the evidence produced to date to explore this issue.

Materials and Methods {#s2}
=====================

Search strategy {#s2a}
---------------

We searched all published studies in the Pubmed database (up to January 20, 2014) using the following combination of keywords: "Apolipoprotein E" OR "ApoE" AND "acute coronary syndrome" OR "myocardial infarction" AND "polymorphism" OR "polymorphisms" OR "variants" OR "variant". In addition, manual searches for related articles were also performed to avoid missing any relevant studies.

Inclusion and exclusion criteria {#s2b}
--------------------------------

The inclusion criteria for identified articles were as follows: 1) Case-control studies with full text articles on the relationship of ApoE polymorphisms and MI; 2) sufficient data for estimating an odds ratio (OR) with 95% confidence interval (CI). Those not designed as case-control studies, systemic reviews, those not written in English or Chinese, and those that provided no usable data, were excluded.

Data extraction {#s2c}
---------------

Two authors independently extracted the data from all included studies using a predesigned data extraction table. The following information was extracted from each included article: first author, year of publication, ethnicity and country, source of controls, total numbers of MI cases and controls, distribution of genotypes and alleles in MI cases and controls, and evidence of conforming to the Hardy-Weinberg equilibrium (HWE).

Statistical analysis {#s2d}
--------------------

We firstly used chi-squared (χ^2^) test and and I^2^ statistic to assess heterogeneity across studies. A fixed effect model (Mantel--Haenszel) was used in the absence of heterogeneity. Otherwise, the random effect model (DerSimonian--Laird) was adopted. The strength of the association between the ApoE gene polymorphism and MI was assessed by odds ratios (ORs) with the corresponding 95% CI for each study. The ORs and their 95% CIs were assessed for the following seven genetic models: 1) ε2ε2 *vs*. ε3ε3; 2) ε2ε3 *vs*. ε3ε3; 3) ε2ε4 *vs*. ε3ε3; 4) ε3ε4 *vs*. ε3ε3; 5) ε4ε4 *vs*. ε3ε3; 6) ε2 vs. ε3; 7) ε4 vs. ε3. The allele frequencies of ε2, ε3 and ε4 were also assessed using the same method. Cumulative meta-analysis was also performed for the above genetic models. Subgroup analysis for ethnicity (Asian and Caucasian) was also performed. To find potential outliers, influence analysis was performed by omitting each study in turn. A funnel plot, calculated using Begg's and Egger's tests, was adopted for assessing potential publication bias. Statistical analysis was conducted using STATA statistical software (version 11; StataCorp, College Station, Texas, USA). A P value less than 0.05 was considered statistically significant.

Results {#s3}
=======

Literature selection and study characteristics {#s3a}
----------------------------------------------

One hundred and thirty two articles were retrieved from PubMed, 79 of which were excluded after screening the titles and abstracts (58 were irrelevant studies, 13 were reviews and eight were not published in English or Chinese). Fifty-three articles were selected for detailed assessment, which excluded a further 20 articles (seven were not case-control studies, eight had no usable data (no case and control numbers according to the genotypes) and five were not about MI). Finally, 33 studies were included in this meta-analysis, which included 18752 MI cases and 18963 controls. The detailed selection procedure is shown in [**Figure 1**](#pone-0104608-g001){ref-type="fig"}. There were three studies did not follow the HWE. The detailed characteristics of the included studies are shown in [**Table 1**](#pone-0104608-t001){ref-type="table"}. The present study met the PRISMA statement requirements ([**Checklist S1**](#pone.0104608.s009){ref-type="supplementary-material"} and [**Figure 1**](#pone-0104608-g001){ref-type="fig"}).

![Flowchart of the study selection.](pone.0104608.g001){#pone-0104608-g001}

10.1371/journal.pone.0104608.t001

###### Detailed characteristics of studies included in this meta-analysis.

![](pone.0104608.t001){#pone-0104608-t001-1}

                                                                                                          Genotypes distribution (Cases/controls)                                                                               
  -------------------------------------------- ------ -------------- ----------- ----- ----- ----------- ----------------------------------------- --------- ----------- ---------- ----------- ------- ----------- ----------- -----------
  Utermann1984[@pone.0104608-Utermann1]         1984     Germany      Caucasion   HCC   Yes   523/1031                     7/120                    x68/124    333/617     11/15      92/236     12/29    86/359      493/977     115/280
  Cumming1984[@pone.0104608-Cumming1]           1984     Scotland     Caucasion   PCC   Yes    239/400                      0/2                      18/51     128/233     10/11       77/99      6/4      28/64      223/383     93/114
  Lenzen1986[@pone.0104608-Lenzen1]             1986      France      Caucasion   PCC   Yes    570/624                      1/6                      50/67     360/393     10/20      137/125    12/13     61/93      547/585     159/158
  Eichner 1993[@pone.0104608-Eichner1]          1993       USA        Caucasion   PCC   Yes    114/412                      0/2                      16/35     67/276       0/4        30/85     1/10      16/41      113/396      31/99
  Luc 1994[@pone.0104608-Luc1]                  1994      France      Caucasion   PCC   Yes    574/680                      3/6                      54/92     352/428     14/14      133/126    18/14    71/112      539/646     165/154
  Hergenc 1995\'[@pone.0104608-Hergenc1]        1995      Turkey      Caucasion   HCC   Yes     50/60                       0/0                       7/6       41/47       0/2         2/5       0/0       7/8        50/58        2/7
  Kim 1995[@pone.0104608-Kim1]                  1995      Korea         Asian     HCC   Yes    97/137                       2/1                      17/25      57/95       0/4        20/12      1/0      19/30      94/132       21/16
  Nakai 1998[@pone.0104608-Nakai1]              1998      Japan         Asian     PCC   Yes    254/422                      0/0                      10/16     178/327      2/4        52/74      6/1      12/20      240/417      60/79
  Scaglione1999[@pone.0104608-Scaglione1]       1999      Italy       Caucasion   HCC   No      98/98                       NR                        NR         NR          NR         NR        NR        3/3        84/87       11/8
  Lambert 2000[@pone.0104608-Lambert1]          2000      France      Caucasion   PCC   Yes    567/678                      3/4                     67/100     332/420      0/3       152/138    18/13    70/107      551/658     170/154
  Benes2000[@pone.0104608-Benes1]               2000      Czech       Caucasion   PCC   Yes    114/222                      1/0                      12/30     71/147       3/2        23/43      4/0      16/32      106/220      30/45
  Batalla 2000[@pone.0104608-Batalla1]          2000      Spain       Caucasion   PCC   Yes    220/200                      0/0                      9/18      174/151      1/1        32/28      4/2      10/19      215/197      37/31
  Raslová 2001[@pone.0104608-Raslova1]          2001      Canada      Caucasion   PCC   Yes     69/69                       2/1                       8/5       46/47       1/0        11/15      1/1      11/6        65/67       13/16
  Bai 2001[@pone.0104608-Bai1]                  2001      China         Asian     PCC   Yes     47/50                       0/0                       4/5       40/39       0/0         6/3       0/0       4/5        50/47        6/3
  Freitas 2002[@pone.0104608-Freitas1]          2002    Australia     Caucasion   PCC   Yes    411/624                      3/4                      24/67     254/372      9/15      111/147    10/19     36/86      389/586     130/181
  Mamotte 2002[@pone.0104608-Mamotte1]          2002    Australia     Caucasion   PCC   Yes    359/639                      4/4                      24/68     217/383      7/16      96/149     11/19     35/88      337/600     114/184
  Kolovou 2002[@pone.0104608-Kolovou1]          2002      Greece      Caucasion   PCC   Yes    124/240                      0/0                      3/34      94/159       0/5        27/40      0/2      3/39       124/233      27/47
  Keavney 2003[@pone.0104608-Keavney1]          2003        UK        Caucasion   PCC   Yes   4487/5757                     NR                      440/686   2566/3384      NR      1206/1376    NR      440/686    4212/5446   1206/1376
  Kolovou 2003[@pone.0104608-Kolovou2]          2003      Greece      Caucasion   PCC   Yes    165/165                      0/0                      3/16      129/118      1/4        29/23      1/0      4/20       161/157      31/27
  Kumar 2003[@pone.0104608-Kumar1]              2003      India       Caucasion   PCC   Yes     35/45                       0/2                       6/9       12/32       1/0         6/0      10/2       7/9        24/41       17/2
  Marques 2003[@pone.0104608-MarquesVidal1]     2003      France      Caucasion   HCC   Yes    400/338                      NR                        NR       272/228       NR         NR        NR       37/40      272/228      91/70
  Keavney 2004[@pone.0104608-Keavney2]          2004        UK        Caucasion   PCC   Yes   4685/3460                     NR                      440/406   2566/1949   1206/810      NR        NR     1646/1216   3006/2355   1206/810
  Ranjith 2004[@pone.0104608-Ranjith1]          2004   South Africa   Caucasion   PCC   Yes    195/300                      0/3                      7/18      139/228      3/3        45/43      1/5      10/24      191/289      49/51
  Baum 2006[@pone.0104608-Baum1]                2006      China         Asian     PCC   Yes    231/331                      0/2                      13/60     164/203      4/6        46/39      4/1      17/68      223/302      54/46
  Aasvee 2006[@pone.0104608-Aasvee1]            2006     Estonia      Caucasion   PCC   Yes     71/85                       1/1                      4/13       45/52       2/3        16/16      3/0      7/17        65/81       21/19
  Koch 2008[@pone.0104608-Koch1]                2008     Germany      Caucasion   PCC   Yes   3657/1211                    26/7                     402/164   2279/736     63/23      809/263    78/18    491/194    3490/1163    950/304
  Kolovou 2009[@pone.0104608-Kolovou3]          2009      Greece      Caucasion   PCC   Yes    124/240                      NR                        NR         NR          NR         NR        NR       5/19       106/197      13/24
  Bahri 2008[@pone.0104608-Bahri1]              2008     Tunisia      Caucasion   PCC   Yes    80/100                       0/0                       6/8       61/78       0/1        13/13      0/0       6/9       80/199       13/14
  Martinelli 2009[@pone.0104608-Martinelli1]    2009      Italy       Caucasion   HCC   Yes    394/287                      NR                        NR         NR          NR         NR        NR       34/25      285/220      76/42
  Al-Bustan 2009[@pone.0104608-AlBustan1]       2009     Kuwaiti      Caucasion   HCC   No     88/122                       4/9                       2/2       72/98       2/3         8/9       0/1      6/11        90/33       16/5
  Onrat 2012[@pone.0104608-Onrat1]              2012      Turkey      Caucasion   PCC   Yes    36/100                       0/0                      12/4       72/27       0/0        16/4       0/1      12/4       100/35       16/5
  Tanguturi 2013[@pone.0104608-Tanguturi1]      2013       USA        Caucasion   HCC   Yes    202/210                      0/0                      8/14      142/167      4/3        37/23     11/3      12/17      187/204      52/29
  Zende 2013[@pone.0104608-Zende1]              2013      India       Caucasion   HCC   No     150/150                      6/7                      13/16      59/85       7/4        22/14     43/24     26/27      94/115       72/42

HWE, Hardy-Weinberg equilibrium; NR, not reported; Cases, MI patients; HCC, hospital based case-control study; PCC, population based case-control study.

Quantitative data synthesis {#s3b}
---------------------------

The meta-analysis of the included studies showed that there was significant association between the ApoE gene polymorphism and MI. The results showed that the MI patients had a decreased frequency of the ε2 allele (OR = 0.78, 95% CI = 0.70--0.87, [**Figure 2**](#pone-0104608-g002){ref-type="fig"}) and an increased frequency of the ε4 allele (OR = 1.15, 95% CI = 1.10--1.20, [**Figure 3**](#pone-0104608-g003){ref-type="fig"}). The results also showed a decreased susceptibility of MI in the ε2ε3 *vs*. ε3ε3 analysis (OR = 0.79, 95% CI = 0.68--0.90, **[Figure S1](#pone.0104608.s001){ref-type="supplementary-material"}**), and in the ε2 *vs*. ε3 analysis (OR = 0.78, 95% CI = 0.69--0.89, **[Figure S4](#pone.0104608.s004){ref-type="supplementary-material"}**), and an increased susceptibility of MI in the ε3ε4 *vs*. ε3ε3 analysis (OR = 1.26, 95% CI = 1.12--1.41, **[Figure S2](#pone.0104608.s002){ref-type="supplementary-material"}**) in the ε4ε4 *vs*. ε3ε3 analysis (OR = 1.59, 95% CI = 1.15--2.19, **[Figure S3](#pone.0104608.s003){ref-type="supplementary-material"}**) and in the ε4 *vs*. ε3 analysis (OR = 1.22, 95% CI = 1.12--1.32, **[Figure S5](#pone.0104608.s005){ref-type="supplementary-material"}**). However, there were no significant associations among polymorphisms and MI for the following genetic models: frequency of ε3 allele (OR = 0.99, 95% CI = 0.96--1.02); ε2ε2 *vs*. ε3ε3 analysis (OR = 0.73, 95% CI = 0.40--1.32); ε2ε4 *vs*. ε3ε3 analysis (OR = 1.10, 95% CI = 0.99--1.21). The detailed results are shown in [**Table 2**](#pone-0104608-t002){ref-type="table"}. Cumulative analysis further confirmed the results ([**Figure 4**](#pone-0104608-g004){ref-type="fig"} and **[Figure S6](#pone.0104608.s006){ref-type="supplementary-material"}**).

![Forest plot for ApoE gene polymorphism and MI risk in the ε2 allele frequency analysis.](pone.0104608.g002){#pone-0104608-g002}

![Forest plot for ApoE gene polymorphism and MI risk in the ε4 allele frequency analysis.](pone.0104608.g003){#pone-0104608-g003}

![Cumulative meta-analysis of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.](pone.0104608.g004){#pone-0104608-g004}

10.1371/journal.pone.0104608.t002

###### Results of meta-analysis of ApoE polymorphism and MI.

![](pone.0104608.t002){#pone-0104608-t002-2}

                                      Overall          Caucasion           Asian                                             
  ----------------------------- ------------------- --------------- ------------------- --------------- -------------------- ---------------
  **ε2ε2 vs. ε3ε3**              0.73 (0.40--1.32)    0.29/0.005     0.70 (0.38--1.31)    0.27/0.004     1.07 (0.08--13.78)     0.96/0.18
  **ε2ε3 vs. ε3ε3**              0.79 (0.68--0.90)    0.001/0.001    0.80 (0.70--0.92)    0.001/0.008    0.70 (0.31--1.60)     0.84/0.007
  **ε2ε4 vs. ε3ε3**              1.10 (0.99--1.21)     0.07/0.70     1.10 (1.00--1.21)     0.05/0.63     0.66 (0.26--1.70)      0.39/0.61
  **ε3ε4 vs. ε3ε3**              1.26 (1.12--1.41)   \<0.001/0.001   1.23 (1.09--1.38)    0.001/0.001    1.51 (1.14--2.00)     0.004/0.39
  **ε4ε4 vs. ε3ε3**              1.59 (1.15--2.19)    0.005/0.04     1.47 (1.07--2.02)     0.02/0.05     6.95 (1.75--27.65)    0.006/0.85
  **ε2 vs. ε3**                  0.78 (0.69--0.89)   \<0.001/0.04    0.80 (0.71--0.90)   \<0.001/0.04    0.67 (0.37--1.23)      0.20/0.22
  **ε4 vs. ε3**                  1.22 (1.12--1.32)   \<0.001/0.02    1.20 (1.10--1.30)   \<0.001/0.02    1.49 (1.15--1.93)    0.002/\<0.001
  **ε2 allele** **frequency**    0.78 (0.70--0.87)   \<0.001/0.001   0.79 (0.71--0.88)   \<0.001/0.005   0.65 (0.38--1.13)      0.13/0.09
  **ε3 allele** **frequency**    0.99 (0.96--1.02)     0.38/1.00     0.99 (0.96--1.02)     0.39/1.00     0.99 (0.86--1.13)      0.22/0.94
  **ε4 allele** **frequency**    1.15 (1.10--1.20)    0.001/0.17     1.14 (1.09--1.19)    0.001/0.18     1.47 (1.14--1.89)     0.003/0.70

P, p value of the test on the association estimate; Phet, p value of the heterogeneity test.

Tests of heterogeneity and subgroup analysis {#s3c}
--------------------------------------------

Significant between-study heterogeneity existed in the analyses of seven genetic models: ε2 ε2 *vs*. ε3ε3 (p = 0.005); ε2ε3 *vs*. ε3ε3 (p = 0.001); ε3ε4 *vs*. ε3ε3 (p = 0.001); ε4ε4 *vs*. ε3ε3 (p = 0.04), ε2 *vs*. ε3 (p = 0.04), ε2 *vs*. ε3 (p = 0.02) and the ε2 allele frequency (p = 0.001). A random effects model was adopted for these analyses.

Furthermore, we performed subgroup analysis based on ethnicity and found a decreased susceptibility of MI in the ε2ε3 *vs*. ε3ε3 analysis (OR = 0.80, 95% CI = 0.70--0.92) and ε2 allele frequency (OR = 0.79, 95% CI = 0.71--0.88) among Caucasian populations. We also found an increased susceptibility of MI in the ε3ε4 *vs*. ε3ε3 analysis (OR = 1.23, 95% CI = 1.09--1.38), ε4ε4 *vs*. ε3ε3 analysis (OR = 1.47, 95% CI = 1.07--2.02) and the ε4 allele frequency (OR = 1.14, 95% CI = 1.09--1.19) among Caucasian populations. Among Asian populations, we also found an increased susceptibility of MI in the ε3ε4 *vs*. ε3ε3 analysis, ε4ε4 *vs*. ε3ε3 analysis and for the ε4 allele frequency; the detailed results are shown in [**Table 2**](#pone-0104608-t002){ref-type="table"}.

Sensitivity analysis {#s3d}
--------------------

We conducted influence analysis to assess the sensitivity of each individual study on the pooled ORs by sequential omission of each individual study. The results suggested that no individual study significantly affected the pooled ORs in the ε2 allele and ε4 allele frequency analysis ([**Figure 5**](#pone-0104608-g005){ref-type="fig"}), and in the ε2ε3 *vs*. ε3ε3 analysis, ε3ε4 *vs*. ε3ε3 analysis and ε4ε4 *vs*. ε3ε3 analysis (**[Figure S7](#pone.0104608.s007){ref-type="supplementary-material"}**).

![Influence analysis of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.](pone.0104608.g005){#pone-0104608-g005}

Publication bias {#s3e}
----------------

Funnel plots examined potential publication bias qualitatively and no obvious asymmetry was observed in any genetic model, as shown in [**Figure 6**](#pone-0104608-g006){ref-type="fig"}. Furthermore, the results from Begg's and Egger's tests did not provide any evidence of publication bias (**[Table S1](#pone.0104608.s008){ref-type="supplementary-material"}**).

![Funnel plot of ApoE gene polymorphism and MI risk: A) ε2 allele frequency analysis; B) ε4 allele frequency analysis.](pone.0104608.g006){#pone-0104608-g006}

Discussion {#s4}
==========

To the best of our knowledge, this is the first meta-analysis to evaluate the association between an ApoE polymorphism and susceptibility of MI. In this meta-analysis, we discovered an increased susceptibility of MI in the ε4 allele frequency analysis. Moreover, the individuals with ε2ε4 genotype, ε3ε4 genotype and ε4ε4 genotype had a significantly higher susceptibility of developing MI compared to those with the ε3ε3 genotype. Therefore, it is reasonable to assume that the ε4 allele of ApoE is an risk factor for the development of MI. These results were consistent with a previous meta-analysis, which showed that ε4 allele of ApoE is a risk factor for the development of CHD [@pone.0104608-Zhang1], [@pone.0104608-Shin1]. In addition, we found a decreased susceptibility of MI in the ε2 allele frequency analysis and in the ε2ε3 vs. ε3ε3 analysis, which indicate that the ε2 allele is a protective factor in the development of MI. Cumulative meta-analysis also confirmed these findings. Considering the large sample size in the pooled analysis in this meta-analysis, we believe that our results are robust and reliable.

ApoE is a multifunctional protein that plays an important role in the metabolism of cholesterol and triglycerides, by binding to its receptors to help mediate clearance of chylomicron and remnant particles [@pone.0104608-Eichner2]. The three common isoforms, ε2, ε3 and ε4, have different receptor-binding abilities and could yield different circulating levels of cholesterol and triglycerides. Compared with ε3 homozygotes, carriers of the ε2 allele have lower circulating cholesterol levels, whereas carriers of the ε4 allele appear to have higher plasma levels of total and low-density lipoprotein cholesterol [@pone.0104608-Dallongeville1]. According to these mechanisms, our meta-analysis suggested that carrying the ε4 allele is a risk factor for MI and that the ε2 allele has a protective role in the development of MI. When stratifying the studies by ethnicity, the ε4 allele remained a risk factor and the ε2 allele was still protective in the development of MI among Caucasian populations; however, only the ε4 allele remained as a risk factor for MI among Asian population. This may be due to the small sample size in the analysis among Asian populations; in fact, there were only four studies that included Asian populations [@pone.0104608-Yin1], [@pone.0104608-Utermann1], [@pone.0104608-Kim1], [@pone.0104608-Kolovou1]. Therefore, further studies are warranted among Asian populations. In addition, genotype distributions in the controls from Scaglione's study [@pone.0104608-Scaglione1], Bustan's study [@pone.0104608-AlBustan1] and Zende's study [@pone.0104608-Zende1] were not in agreement with HWE, therefore, the results may be biased. However, sensitivity analysis suggested that the pooled results were not significantly changed after excluding the three studies (data not shown). This may be due to the large sample size even though the three studies were excluded.

Although the primary results of this meta-analysis are suggestive, some limitations still exist. First, between-study heterogeneity existed in some of the genetic model analysis, which may have affected the results of the present meta-analysis, although a random effects model was adopted for these analyses. Second, publication bias may have occurred because our analyses were based wholly on published studies only in English and Chinese. Third, the results of this meta-analysis were based on unadjusted estimates because of the lack of adjusted estimates. Currently, some risk factors have been identified for MI, such as hypertension, hypercholesterolemia, diabetes, obesity and smoking. A more precise analysis should be performed if these data could be extracted from primary articles.

In conclusion, this comprehensive meta-analysis has evaluated all published data currently available on the association between the ApoE polymorphism and MI. Our meta-analysis suggested that the ε4 allele of ApoE is an risk factor for the development of MI and the ε2 allele of ApoE is a protective factor in the development of MI. This may be explained by the fact that ε4 allele of ApoE elevates the plasma levels of total and low-density lipoprotein cholesterol while the ε2 allele of ApoE lowers the circulating cholesterol levels. Further studies with larger sample sizes are warranted among Asian populations.
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